I have more than 20 years of research experience in the Pharmaceutical industry mainly from discovery and development of small molecules therapeutics and during the last 5 years also from RNA based therapeutics. I have broad experience of management of departments and teams as well as setting and delivering business strategies. I am also involved in several collaborations with biotech companies as well as with academic groups around the globe.
I obtained a PhD in organic and analytical chemistry in 1989 from Linköping University. After a post-doc in Germany, I joined Linköping University as a Senior lecturer in Organic Analytical Chemistry and became an Associate Professor (Docent) in 1996 during which time I also gave birth to 2 children. In 1997, I joined AstraZeneca as a senior researcher and during my career I have held numerous management roles including Senior Director Drug Metabolism and Pharmacokinetics, Head of Enabling Technologies and Head of Lead Optimization, Medicinal Chemistry. I am currently a Head of New Therapeutic Modalities, Cardiovascular, Renal and Metabolic Innovative Medicines unit (CVRM IMED) in AstraZeneca. I have strong experience as a project leader for research projects and business change projects locally and globally within AstraZeneca. I am currently leading the CVRM Delivery of new therapeutic modalities and Targeted Drug Delivery platform projects and I am involved in collaborations with Ionis Pharma, Moderna Therapeutics and MMBio (EU funded) within the RNA field. I have over 40 peer reviewed publications, 2 book chapters and 4 patents and have presented my work at conferences throughout my career including chairing sessions at conferences.
European Cooperation in Science and Technology network on Delivery of RNA therapy
Oligonucleotide Therapeutic Soc.
Swedish Chemical Soc.
Swedish Academy of Pharmaceutical Sciences
American Chemical Soc & AAPS